DiCE Molecules

About DiCE Molecules

Dice Molecules is a biotechnology startup that focuses on the development of innovative oral medicines for the treatment of chronic autoimmune and inflammatory diseases. The company's primary target market includes patients suffering from conditions such as psoriasis and other diseases mediated by the IL-17 cytokine.

The company operates in the biotechnology and pharmaceutical industry, specifically in the immunology sector. Its business model revolves around the development and commercialization of its proprietary DELSCAPE platform. This platform is designed to identify selective oral small molecules that can modulate protein-protein interactions (PPIs), which are the same interactions targeted by currently available biologics.

Biologics are a type of drug derived from living organisms that are used to treat diseases. However, they often require administration through injections or intravenous infusions and regular patient monitoring. Dice Molecules' approach aims to overcome these challenges by developing oral medicines that are as effective as these biologics, but more convenient for patients.

The company generates revenue through the development and potential sale of its therapeutic candidates. As these candidates progress through clinical trials and receive regulatory approval, Dice Molecules can commercialize these drugs, either independently or through partnerships with larger pharmaceutical companies.

In summary, Dice Molecules is a pioneering biotech startup that is developing a new approach to immunology, aiming to transform the treatment landscape for chronic autoimmune and inflammatory diseases with its innovative oral medicines.